SCHEMBL6477190

SCHEMBL6477190

CCOC(=O)C=Cc1ccc(OCOC)c(Br)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.60
MAPT P10636 1/20 0.57
MAOB P27338 1/20 0.56
TTR P02766 1/20 0.54
DPP4 P27487 1/20 0.54
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
ACHE P22303 4/20 0.50
BCHE P06276 3/20 0.50
CYP3A4 P08684 2/20 0.49
HPGD P15428 1/20 0.47
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CTSL P07711 3/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477187 1.00 FDPS (0.60) FDPSMAPTMAOBTTRDPP4
SCHEMBL29412920 0.90 FDPS (0.60) FDPSMAPTMAOBTTRDPP4
SCHEMBL2389148 0.87 FDPS (0.70) FDPSMAPTMAOBTTRDPP4
SCHEMBL6472764 0.87 FDPS (0.70) FDPSMAPTMAOBTTRDPP4
SCHEMBL14143303 0.86 FDPS (0.73) FDPSMAPTMAOBTTRDPP4
SCHEMBL14501336 0.86 FDPS (0.73) FDPSMAPTMAOBTTRDPP4
SCHEMBL7584892 0.84 MAPT (0.62) MAPTCA12CA1CA2CA7
SCHEMBL7584890 0.84 MAPT (0.62) MAPTCA12CA1CA2CA7
SCHEMBL14816553 0.82 TTR (0.57) FDPSMAOBTTRDPP4CA12
SCHEMBL9515291 0.81 TTR (0.66) FDPSMAOBTTRDPP4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R FDPS 3696/4885MAPT 2429/4885MAOB 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.